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Pooled Relative Risk for at least one relapse in four trials including all doses was 0.7, 
a non-signiﬁcant RR (95% CI: 0.42–1.17, P  0. 17). Summary RR for at least one 
relapse in two trials in which doses of 3 mg/kg or 6 mg/kg or 300 mg every 4 weeks 
were administered gave a values of 0.5 as a signiﬁcant RR (95% CI: 0.42–0.61, P  
0.0001). The summary RR for at least one new Gd-enhancing lesion was 0.22, a 
non-signiﬁcant RR (95% CI: 0.05–1.01, P  0.051). Three deaths were reported in 
natalizumab group. Comparing adverse events between natalizumab and placebo 
yielded a non signiﬁcant RR of 0.99 (95% CI: 0.96–1.01, P  0.34) for any adverse 
events (n  3), and a signiﬁcant RR of 0.39 (95% CI: 0.29–0.52, P  0.0001) for 
serious adverse events (n  2). A summary RR for withdrawal due to adverse events 
by natalizumab vs. placebo therapy between two trials was 1.43, a non-signiﬁcant RR 
(95% CI: 0.68–3.02, P  0.35). CONCLUSIONS: It seems that using 3 mg/kg or 
6 mg/kg every four weeks is the best experienced method of administration of natali-
zumab for preventing relapse and occurrence of new Gd-enhancing. Further clinical 
trials are still needed.
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OBJECTIVES: Multiple Sclerosis (MS) is a chronic, recurrent, inﬂammatory disease 
with unrelenting attacks from the immune system. It is the major cause of non-
 traumatic disability in young adults. Iran, contrary to the other countries in Middle-
east, is considered to have a high prevalence of MS that mentioned as the National 
disaster in Iran. While much is known about the MS in the world, there is a paucity 
of the feature of MS in Iran. METHODS: In a 6-month cross-sectional study 248 MS 
patients were studied in Iran. Data was collected by employing a 32- item self-admin-
istered questionnaire. Parametric, nonparametric tests and descriptive statistics analy-
sis were applied (p value 0.05). RESULTS: The prevalence and incidence was 
estimated to be 25/100000 and 2.5/100,000, respectively. The patients were diagnosed 
in 2001 onward were more frequently than the patients in1981–1990(40:1). The mean 
age 31.9 o 8.7, the mean onset age 26.3(26.3 o 8:1) and the mean duration of illness 
were 5.6 o 5.3 years. A family history of ms was reported in 11%. The sex ratio was 
3:1(female : male). CONCLUSIONS: In contrast to reports from Caucasians , MS 
Iranian population signiﬁcantly differ with respect to the age, onset age, disease dura-
tion, family history and sex ratio. This might reﬂect the different in some environmen-
tal-genetic factors and life style as well, in this population. Some of our ﬁnding were 
comparable to the so-called “western type” of MS such as : BMI, birth season and 
education stand.
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OBJECTIVES: Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) 
approved for the treatment of major depressive disorder (MDD). Following patent 
expiration, venlafaxine is available as generic at a reduced price. We evaluated the 
overall savings to the National Health System (NHS) following venlafaxine’s price 
reduction. METHODS: A simulation model was constructed in Microsoft Excel to 
carry out a Budget Impact Analysis. Three scenarios were hypothesized: the ﬁrst simu-
lation evaluated the potential savings to the NHS following venlafaxine’s price reduc-
tion. The second and third simulations assessed additional potential savings to the 
NHS supposing an increase in the market share of venlafaxine by substitution of dif-
ferent proportions of other branded products namely duloxetine and escitalopram. 
Costs were obtained from IMS Health, efﬁcacy data were derived from the available 
literature. RESULTS: Mean annual treatment cost with venlafaxine decreased from 
a567 to a284 resulting in overall savings to the NHS of more than a44 million per 
year. Treatment switching from escitalopram and/or duloxetine to venlafaxine was 
always a dominant strategy and resulted in a higher number of patients treated more 
efﬁcaciously since venlafaxine performs better in terms of remission and is less expen-
sive. Sensitivity analyses on effectiveness (response) and cost variables conﬁrmed our 
results. CONCLUSIONS: This analysis suggests that extended use of generic venla-
faxine is likely to lead to overall cost savings to the NHS due to its cost-effectiveness 
proﬁle compared with other antidepressants such as duloxetine and escitalopram.
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OBJECTIVES: Previous research identiﬁed hypnotic-users to have a greater risk of 
falls and fractures vs. controls. The objective of this study was to determine the 
economic burden of falls and fractures to managed care among hypnotic users. 
METHODS: A retrospective study was designed using data from a national managed 
care commercial claims database. First time hypnotic-users were identiﬁed using 
pharmacy claims and matched to two controls on gender, region, payer, and age. 
Subjects were followed for 12-months post index-date to capture events and costs of 
falls and fractures identiﬁed using speciﬁc ICD-9-CM and E-codes. Multivariate 
regression models were used to estimate the incremental burden of falls or fractures 
at a per-hypnotic user per year (PHUPY) for a hypothetical managed care plan of 1 
million membership with hypnotic-use rate of 4.5% and stratiﬁed by age-categories: 
young-adults (18–44 yrs), middle-age (45–64 yrs) and elderly (65 yrs). RESULTS: A 
total of 40,549 hypnotic-users and 81,098 controls met the inclusion criteria. Both 
groups were demographically similar (p  0.05) at baseline. Hypnotic-users had higher 
Charlson comorbid index scores (1.07 vs. 0.60, p  0.001) and proportion of balance 
disorders (3.33% vs. 2.18%, p  0.001) compared to controls. For those who had an 
event, the total annual mean direct costs of managing falls and fractures was $2,559 
(95%CI: 2117–3001), and $3294 (95%CI: 2916–3673), respectively, with costs lin-
early increasing with age. Based on hypnotic-use rate of 4.5% and age distribution, 
total hypnotic-users in the hypothetical plan were estimated to be 33,750. Falls/frac-
ture related PHUPY translated into $50 (Range: 24–82), $63 (Range: 39–92), and 
$245 (Range: 28–615) for young, middle-age and elderly hypnotic users. Overall 
burden due to falls/fractures as a consequence of hypnotic use to managed care was 
estimated to be $2,092,500 (Range: 1,451,250–2,801,250) CONCLUSIONS: The 
unintended consequence (i.e. managing falls/fractures) of current hypnotic use may be 
burdensome to a managed care plan.
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OBJECTIVES: Sugammadex (SGX) is a modiﬁed gamma-cyclodextrin that bonds with 
rocuronium and vecuronium, leading to reversal of the neuromuscular blockade. The 
objective of this study was to evaluate the budget impact and the cost-effectiveness of 
SGX in the routine reversal of patients with neuromuscular block (NMB) from the 
Spanish National Health System perspective. METHODS: A decision-analytic (DAM) 
and a budget impact model (BIM) was developed to assess the mean treatment costs 
per patient (a2009), life-years gained (LYG), and incremental cost per LYG of SGX, 
the spontaneous reversal and neostigmine/atropine in the reversal of patients with 
NMB. The DAM simulates the probability of experiencing an adverse effect and the 
direct costs produced by each treatment alternative. The BIM accounts for the time 
that SGX could save in the operating room (OR), shortening the time to extubation, 
thereby accelerating the movement of patients in and out of the OR. Clinical data was 
obtained from the clinical trial performed with SGX, the SmPC of each drug and form 
secondary sources. Costs were obtained for Soikos database. RESULTS: In the routine 
reversal of patients, ROCSGX is associated with higher costs than the spontaneous 
reversal or neostigmine/atropine but also with higher LYG. The cost-effectiveness 
range of SGX vs. neostigmine/atropine varies between a13,26 and 4,976 per LYG, 
and vs. spontaneous reversal between a6,880 and 17,657 per LYG. In the BIM, SGX 
could save between 108 and 171 minutes of OR, that would mean that 1 or 2 more 
surgeries could be performed, and a total budget saved between a1400 and 2000 per 
OR per day. CONCLUSIONS: Under the established assumptions, SGX would be a 
cost-effective alternative for the routine reversal of patients with NMB and could be 
a cost-saving strategy due to the increase of the turn over of the OR.
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OBJECTIVES: Relapsing-remitting multiple sclerosis (RRMS) is the most common 
form of multiple sclerosis. Beta interferons have been shown to reduce relapse rates 
by a third. The aim of this study is assessing the value of subcutaneous interferon 
beta-1a when compared to other available disease modifying drugs for RRMS patients 
in Spain. METHODS: Pharmacoeconomic model based on subcutaneous interferon 
beta-1a clinical trials efﬁcacy data (relapses and progression of disability both on the 
medium and long run) and local expert panel. This analysis was undergone from the 
Spanish National Health System (SNHS) perspective, included only direct medical 
costs and employed an annual discount rate of 3% on both costs and health outcomes. 
The model provided estimations of cost per avoided relapse and cost per avoided 
progression, as well as probabilistic sensitivity analysis with 1000 Monte Carlo simu-
lations. Budget impact analysis was also undergone to forecast the implications of 
subcutaneous interferon beta-1a increased market share in a 4-year horizon. RESULTS: 
Subcutaneous interferon beta-1a and natalizumab result in the lowest MS relapse rates 
with an estimated cost per avoided relapse of a28,847, a29,918, a36,299, a42,027 
and a55,379 when subcutaneous interferon beta-1a, interferon beta-1b, glatiramer 
acetate, natalizumab and intramuscular interferon-1a are employed. Cost per avoided 
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progression is a150,000–350,000 for each therapy but glatiramer acetate (a651,796). 
Probabilistic sensitivity analysis conﬁrmed subcutaneous interferon beta-1a and inter-
feron beta-1b as the most cost-effective therapies (conﬁdence intervals remained below 
a45,000 per avoided relapse). Estimated budget impact of assuming 5–9% annual 
increase of subcutaneous interferon beta-1a market share equals 0.17–0.52% of actual 
RRMS cost in Spain. CONCLUSIONS: Subcutaneous interferon beta-1a is an efﬁcient 
strategy for RRMS in Spain as it allows an appropriate management and treatment 
of RRMS relapses and progression with a minor budgetary impact for SNHS.
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OBJECTIVES: Economic evaluation of Lacosamide (LCM) and standard treatment 
with commonly used antiepileptic drugs (ST) vs. ST alone in the Finnish setting. LCM 
is a new antiepileptic drug, indicated for adjunctive treatment of partial-onset seizures 
(POS) with or without secondary generalisation in patients aged 16 years and older. 
METHODS: A probabilistic decision tree based cost-effectiveness analysis (CEA) with 
second-order Monte Carlo simulation and a 2-year time-frame was performed in Excel 
from the Finnish societal perspective (productivity losses and VAT excluded). The 
efﬁcacy data were obtained from the LCM-trials, and the Finnish costs (inpatient, 
outpatient, GP, laboratory, drug) and utilities from published studies. Budget impact 
modelling (BIM) with a ﬁve year time-frame was done to assess the net monetary 
impact of LCM launch to the refractory epilepsy budget. Only drug costs were 
included in BIM. Conservatively, generic prices were used in all analyses. RESULTS: 
According to CEA, LCMST was associated with an incremental cost of a945 (mainly 
related to seizure management and drug acquisition), a gain of 0.040 QALYs and 8.92 
seizures avoided compared to ST alone. LCMST was associated with a cost of 
a23,396 per QALY gained and a106 per seizure avoided compared to ST alone. 
According to the cost-effectiveness acceptability frontier, the probability of LCM’s 
cost-effectiveness was 67.9% and 85.6% with a30,000 and a50,000 per QALY 
gained, respectively. The results were robust in sensitivity analyses. According to BIM, 
the expected annual budget increase due to launch of LCM is a0 in 2008, a7,653 in 
2009, a47,350 in 2010, a134,949 in 2011, and a232,609 in 2012. The relative 
increase in the annual epilepsy budget due to LCM is 0.08% in 2009, 0.46% in 2010, 
1.31% in 2011, and 2.23% in 2012. CONCLUSIONS: LCM is a valuable option for 
POS treatment because of its potential cost-effectiveness and low budget impact.
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OBJECTIVES: Neurostimulators (NS) for DBS are replaced when the battery goes to 
an end-of-life (EOL). Activa® RC, Medtronic’s new rechargeable NS, offers guaranteed 
9 years longevity. The objective was to perform a cost analysis of Activa® RC, vs. 
Kinetra® (previous non-rechargeable NS), based on the number of EOL replacements 
needed. METHODS: The following costs were included (hospital perspective, a, 
2009): 1) DBS acquisition costs; 2) surgical procedure cost: Spanish tariff for Parkin-
son disease surgery; 3) EOL NS’s replacement procedure cost: includes surgical pro-
cedure cost (excluding the acquisition costs of therapy components) and the NS cost. 
The EOL depends on patient energy requirements (disease-related) and on the NS: 
Kinetra®: dystonia patients replacements every 2 years; Parkinson disease, every 3–4 
years; essential tremor, every 4–5 years(expert opinion). Activa® RC: every 9 years for 
all indications. Cumulative costs/year was obtained for a 9-years timeframe to 
compare the costs and number of surgical replacements avoided with Activa® RC. The 
main cost driver, surgical procedure cost, was changed as a sensitivity analysis (SA). 
RESULTS: Thanks to higher battery longevity, the following savings could be 
obtained: 1) Dystonia patients, as higher energy requirement are needed, higher eco-
nomic beneﬁts are observed: at year a9, 57.585 saved/patient or 4 EOL-replacement 
avoided; 2) Parkinson disease, at year 9, 2 replacements are avoided, that represents 
a21.867 saved/patient; 3) Essential tremor, savings oscillates between a4.008-a21.867, 
avoiding 1–2 EOL-replacement in 9 years. CONCLUSIONS: Although initial acquisi-
tion costs of Activa® RC are higher, compared to Kinetra®, those are compensated 
after the ﬁrst Kinetra®’s EOL surgical replacement, obtaining important cost savings 
at year 9 (4.008a-57.585a/patient), avoiding 1–4 surgical replacements. The more 
energy requirements, the higher economic beneﬁts are observed with Activa® RC. An 
adequate patient selection is needed to maximize clinical and economic beneﬁts of 
Activa® RC-DBS.
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OBJECTIVES: Activa®, Medtronic’s DBS, is an effective,safe and reversible therapy 
for Parkinson disease, essential tremor and dystonia. A cost analysis was perform to 
estimate the economic beneﬁts related to 2 features of Activa PC® family, new DBS 
generation devices, and the net Budget impact (BI) for Spanish hospitals, compared 
to Kinetra®. METHODS: The 2 features: neurostimulator’s (NE) lower size and new 
stretchable extensions; both can avoid some adverse events (AEs) associated with 
Kinetra (no other beneﬁts were considered). A literature search was done to retrieve 
safety studies. Selection criteria: AEs related with NE &/or the extension, their inci-
dence and detailed treatment description. Health resource use was assigned to AEs 
treatment (Spanish hospital costs, Euros 2009): regional tariffs; acquisition costs. A 
net cost for each AEs was obtained, multiplying each AEs treatment incidence by its 
total cost. Total cost obtained with Activa PC®, compared to Kinetra®, corresponds 
to savings/patient. The net BI for Spanish hospitals was calculated: total incremental 
cost/Activa PC® treated patient instead of Kinetra® (considering AEs avoided and its 
savings). An AE incidence comparison was made as a sensitivity analysis (SA). 
RESULTS: 2 safety studies were selected. The 2 features could avoid 6 AEs, 2 related 
to NEs (hematoma in the NE implant site; infection/erosion); 4 with the extension 
(lead broke after a fall; extension fracture; skin ulceration in the connector; local dis-
comfort). In total, avoiding these AEs involved 591a saved/patient treated with Activa 
PC® family (SA obtained similar data). Including Activa PC® instead of Kinetra family 
in Spanish Hospitals involved a net BI per patient of a1.781. CONCLUSIONS: The 
new Activa PC family may avoid AEs related to the previous generation, Kinetra, with 
a decrease in the total cost per patient. The substitution of Kinetra® for Activa PC® 
family involves a small net budget impact per patient.
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OBJECTIVES: To examine the economic burden of newly diagnosed multiple sclerosis 
(MS) on the US health care system using a large, managed care database. METHODS: 
This was a retrospective cohort analysis of a large, US claims database. Cases were 
deﬁned as having either an MS diagnosis (ICD-9-CM 340) on at least 2 claims or 1 
prescription for MS treatment (glatiramer acetate, interferon betas, or natalizumab) 
between 2004 and 2006. The index date was the ﬁrst qualifying diagnosis or prescrip-
tion. We excluded patients with an MS diagnosis or treatment over the 12 month 
pre-index period, or without continuous enrollment from 12 months pre- to 12 
months post-index date. Each case had 5 controls without MS diagnoses or treatment 
matched on geographic region, insurance type, gender, relation to employee, age and 
lack of comorbid conditions with a similar period of continuous enrollment. Use of 
services was compared using chi-square tests, and 2008 adjusted costs were compared 
using the Wilcoxon rank-sum nonparametric tests. RESULTS: There were 1412 cases 
and 7,060 matched controls in the study. Sixty-six percent of the study population 
was female. MS patients were twice as likely to have emergency department (ED) visits 
(25.5% vs. 12.2%), 1.3 times as likely to have physician ofﬁce visits (95.8% vs. 
75.1%), and 2.4 times as likely to have used physical therapy (all p-values 0.001) 
services over the follow-up period. MS patients also had higher costs related to these 
services ($380 vs. $166, $614 vs. $228, and $268 vs. $74, respectively; all p-values 
0.001). Total costs for MS patients were signiﬁcantly higher than for controls 
($16,984 vs. $3,639 p  0.001). CONCLUSIONS: Newly diagnosed MS patients 
present a large burden on the health care system with additional 1st-year cost of over 
$13,000. While MS treatment drugs are expensive, this represents only one-third of 
the additional cost of care within the 1st year.
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OBJECTIVES: Migraine is prevalent, and headache-related disability can impact the 
ability of migraineurs to work and perform daily activities. This study examined the 
impact of CM compared to EM on work patterns and productivity across countries. 
METHODS: Web-based survey data were collected from migraineurs in the US, 
Canada, Germany, UK, France, Italy, Spain, Australia, and Taiwan. According to 
ICHD-2 criteria, presence of migraine (past 3-months headaches with pain, nausea, 
and photophobia/phonophobia) and q15 headache days/month indicated CM, and 
14 headache days/month indicated EM. Questions on absenteeism and presenteeism 
(reduced efﬁciency) in the preceding 4 weeks assessed headache impact on work or 
school. Linear and logistic regressions, as appropriate, compared migraine group and 
adjusted for age, gender, race, education, comorbidities, and country. RESULTS: Of 
63,001 invitees, 20,987 responded. A total of 9,118 completers (14.5%) comprised 
the ﬁnal cohort [n  516 (Australia) to 1597 (US)]; 83.6% female; 5.5% CM, 90.2% 
EM. CM respondents were 1.4 times more likely than EM to report that they had 
missed any work/school due to headache (95% CI  1.1, 1.8). CM reported missing 
a higher number of work/school days due to headache symptoms than EM (adjusted 
mean o SE  8.83 o 0.59 vs. 4.05 o 0.44, p  0.0001), as well as working more days 
